As of March 2025, several weight loss medications have emerged or are under development:
Zepbound (tirzepatide): Approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adults with obesity or overweight conditions. Clinical trials demonstrated an average weight loss of approximately 20.9% of starting weight at the highest dose.
Mounjaro (tirzepatide): Recently launched in India following approval from the country's drug regulator. This reflects a global trend in addressing rising obesity and diabetes rates.
CagriSema (cagrilintide/semaglutide): A combination of cagrilintide and semaglutide, currently in Phase III clinical trials. Preliminary results indicate an average weight loss of 20.4% over 68 weeks, suggesting potential efficacy comparable to existing treatments.
CT-388: A novel dual GLP-1 and GIP receptor modulator under development by Roche/Genentech. Early trials have shown promising results, with participants experiencing significant weight loss over a 24-week period.
While these medications offer new avenues for weight management, it's essential to consult with healthcare professionals to determine the most appropriate treatment based on individual health profiles and to understand potential side effects.
Continue With Google 
Continue With Facebook 
Medicines
Health
Pharmaceutical
